🇺🇸 FDA
Pipeline program

Drug-AZD8931

D0102C00019

Phase 1 small_molecule terminated

Quick answer

Drug-AZD8931 for Breast Neoplasm is a Phase 1 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Breast Neoplasm
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials